Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Transducer-like Enhancer of Split 1 as a Novel Immunohistochemical Marker for Diagnosis of Synovial Sarcoma

  • Atef, Aliaa (Pathology Department,Faculty of Medicine, Tanta University) ;
  • Alrashidy, Mohammed (Pathology Department,Faculty of Medicine, Tanta University)
  • Published : 2015.10.06
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Synovial sarcoma is a mesenchymal neoplasm that accounts for around 10% of all soft tissue sarcomas. The diagnosis of synovial sarcoma can be a challenging task, particularly with small biopsy specimens. Aim: We investigated transducer-like enhancer of split 1 (TLE1), monoclonal antibody, expression by immunohistochemical analysis in a group of 74 synovial sarcoma cases, 20 cases of MPNST, 12 cases of neurofibroma, 15 cases of schwannoma, 5 cases of MFH, 10 cases of lieomyosarcoma and 10 cases of solitary fibrous tumor. Materials and Methods: Whole tissue sections were examined: (39 biphasic and 35 monophasic). Nuclear immunoreactivity was scored as negative (<5% of cells positive), 1+(mild /5-25%), 2+ (moderate/25-50%), and 3+ (strong >50%). Results: Overall, 71 (96%) of 74 synovial sarcomas were positive for TLE1, including 37 biphasic (95%) and 34 monophasic (97%) tumors. Other spindle cell tumors showed very low or absent staining of TLE1. Conclusions: We conclude that TLE1 is a sensitive marker and can be a useful diagnostic marker for synovial sarcoma, particularly the monophasic forms.

Keywords

References

  1. Amary MF, Berisha F, Bernardi Fdel C, et al (2007). Detection of SS18-SSX fusion transcripts in formalin-fixed paraffinembedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma. Mod Pathol, 20, 482-96. https://doi.org/10.1038/modpathol.3800761
  2. Coindre JM, Pelmus M, Hostein I, et al (2003). Should molecular testing be required for diagnosing synovial sarcoma? a prospective study of 204 cases. Cancer, 98, 2700-7. https://doi.org/10.1002/cncr.11840
  3. Fisher C. (1998). Synovial sarcoma. Ann Diagn Pathol, 2, 401-21. https://doi.org/10.1016/S1092-9134(98)80042-7
  4. Foo WC, Cruise MW, Wick MR. and Hornick JL. (2011). TLE1 distinguishes synovial sarcoma from histologic mimics. Am J Clinical Pathol, 135, 839-44. https://doi.org/10.1309/AJCP45SSNAOPXYXU
  5. Goldblum JR, Folpe AL. and Weiss SW. (2014). Enzinger and Weiss's soft tissue tumors. 6th ed, Elsevier Saunders Press, 1052-70.
  6. Jagdis A, Rubin BP, Tubbs RR, Pacheco M, Nielsen TO. (2009). Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma. Am J Surg Pathol, 33, 1743-51. https://doi.org/10.1097/PAS.0b013e3181b7ed36
  7. Kawauchi S, Fukuda T, Chochi Y, et al (2005). Reverse transcription-polymerase chain reaction in situ hybridization for SYT-SSX fusion gene transcripts in synovial sarcomas. Int J Mol Med, 16, 763-6.
  8. Knosel 21. T, Heretsch S, Altendorf-Hofmann A, Richter P, Katenkamp K, Katenkamp D, et al.(2010). TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X; 18). analysis of 319 cases. Eur J Cancer, 46, 1170-6. https://doi.org/10.1016/j.ejca.2010.01.032
  9. Kosemehmetoglu K, Vrana JA, Folpe AL. (2009). TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms. Mod Pathol, 22, 872-8. https://doi.org/10.1038/modpathol.2009.47
  10. Pelmus M, Guillou L, Hostein I, et al (2002). Monophasic fibrous and poorly differentiated synovial sarcoma: immunohistochemical reassessment of 60 t(X;18)(SYTSSX)-positive cases. Am J Surg Pathol, 26, 1434-40. https://doi.org/10.1097/00000478-200211000-00005
  11. Rekhi B, Basak R, Desai SB. and Jambhekar NA. (2012). Immunohistochemical validation of TLE1, a novel marker for synovial sarcomas. Indian J Med Res, 136, 766-75.
  12. Sadighi S and Raafat J (2003). Sarcoma in Iran. Asian Pac J Cancer Prev, 4, 95-8.
  13. Terry J, Saito T, Subramanian S, et al (2007). TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol, 31, 240-6. https://doi.org/10.1097/01.pas.0000213330.71745.39
  14. Yao J, Liu Y, Lo R, et al (2000). Disrupted development of the cerebral hemispheres in transgenic mice expressing the mammalian Groucho homologue transducin-like-enhancer of split 1 in postmitotic neurons. Mech Dev, 93, 105-15. https://doi.org/10.1016/S0925-4773(00)00278-1

Cited by

  1. TLE1 Expression in Malignant Rhabdoid Tumor and Atypical Teratoid/Rhabdoid Tumor vol.21, pp.6, 2018, https://doi.org/10.1177/1093526618761720
  2. Expression of TLE1 in Malignant Melanoma With Spindle Cell Morphology: A Potential Diagnostic Pitfall pp.1940-2465, 2018, https://doi.org/10.1177/1066896918805137